Dexloxiglumide is a drug which acts as a cholecystokinin antagonist, selective for the CCK<sub>A</sub> subtype. It inhibits gastrointestinal motility and reduces gastric secretions, and despite older selective CCK<sub>A</sub> antagonists such as lorglumide and devazepide having had only limited success in trials and ultimately never making it into clinical use, dexloxiglumide is being investigated as a potential treatment for a variety of gastrointestinal problems including irritable bowel syndrome, dyspepsia, constipation and pancreatitis, and has had moderate success so far although trials are still ongoing.